Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

Leukemia

Volumn 24, Issue 8, 2010, Pages 1523-1525

  Von Bubnoff, N ^a   Rummelt, C ^a   Menzel, H ^a   Sigl, M ^a   Peschel, C ^a   Duyster, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CD135 ANTIGEN; CYTARABINE; DOXORUBICIN; HYDROXYUREA; PROLINE; SORAFENIB; SUNITINIB;

AGED; BLAST CELL; CASE REPORT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DRUG RESPONSE; FEMALE; GENE DUPLICATION; HUMAN; LETTER; LEUKOCYTOSIS; MONOCYTOSIS; PRIORITY JOURNAL; PSORIASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77955710421     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.122     Document Type: Letter

References (10)

1. Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press: Lyon, 2008.
2. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60.
3. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108: 3262-3270.
4. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O0Farrell AM et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML)or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-993.
5. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184-198.
6. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567-6571.
7. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293-300.
8. von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009; 69: 3032-3041.
9. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64: 6385-6389.
10. Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007; 12: 367-380.